AstraZeneca follows GSK with $1.5B annual savings push
Battered by late-stage trial failures and determined to meet its ambitious $80 billion-by-2030 revenue goal, AstraZeneca is cutting costs. The company said Friday that it was shifting resources with ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.